Avenio.ai Names Dr. Megha Vasavada as VP of Product Management to Drive GenAI in Clinical Trials
Avenio.ai has appointed Dr. Megha Vasavada as Vice President of Product Management. In this role, she will lead the product strategy for AvenioGPT, the company’s generative AI platform aimed at improving insight generation and decision-making throughout the clinical trial process.
Dr. Vasavada brings over ten years of experience in clinical research, neuroimaging, and study operations. She has managed multidisciplinary initiatives at UCLA’s Brain Mapping Center and Penn State College of Medicine, contributing to research in diverse therapeutic areas including neuroscience, Alzheimer’s, and mood disorders. Her work on NIH-funded projects has advanced knowledge about biomarkers and treatment responses in major depressive disorder.
Bringing Real-World Clinical Research Experience to AI Product Development
With a background that bridges scientific research and practical implementation, Dr. Vasavada understands the challenges clinical teams face. She has witnessed firsthand how fragmented workflows and manual processes slow trial progress. Her goal at Avenio is to develop AI tools that fit naturally into existing research practices, helping teams work smarter and faster.
“AvenioGPT offers intuitive, research-ready tools that reflect how science is actually done,” Dr. Vasavada said. “This real-world alignment makes the work urgent and inspiring.” She is currently focused on enhancing intelligent clinical documentation and integrating real-world data with scientific literature to speed up clinical insights.
Shaping the Future of Clinical Trial Operations with AI
At Avenio, Dr. Vasavada will guide the evolution of AvenioGPT’s product roadmap. Her work will align product features with sponsor needs, streamline clinical workflows, and maintain scientific credibility across therapeutic areas. This leadership comes at a critical time as AI adoption in pharma accelerates.
Ajay Jotwani, Co-founder and CEO of Avenio.ai, highlighted her unique qualifications: “Megha combines scientific expertise, clinical operations experience, and a user-focused mindset. These qualities are key to building tools that effectively address the real challenges clinical teams encounter.”
Her appointment marks a major step for Avenio as it expands its offerings for life sciences professionals. The company aims to deepen its impact on clinical operations and improve user experience while advancing its vision to become a trusted AI platform for BioPharma.
Why This Matters for Product Development Professionals
- Dr. Vasavada’s leadership underscores the importance of domain expertise when developing AI products for clinical research.
- Integrating AI tools like AvenioGPT into clinical workflows offers a practical way to reduce inefficiencies and improve decision-making.
- Understanding user needs in complex environments is essential for creating effective product roadmaps that deliver real value.
For product developers working at the intersection of AI and healthcare, this appointment signals a growing focus on building AI solutions grounded in clinical realities. It highlights the necessity of combining technical innovation with deep operational insight.
To explore more about AI applications in product development and clinical operations, visit Complete AI Training.
Your membership also unlocks:
